| Literature DB >> 25031606 |
Swee Keong Yeap1, Boon Kee Beh2, Joan Kong3, Wan Yong Ho4, Hamidah Mohd Yusof5, Nurul Elyani Mohamad5, Aminuddin Bin Hussin6, Indu Bala Jaganath7, Noorjahan Banu Alitheen5, Anisah Jamaluddin6, Kamariah Long6.
Abstract
Fermented red yeast rice has been traditionally consumed as medication in Asian cuisine. This study aimed to determine the in vivo hypocholesterolemic and antioxidant effects of fermented red yeast rice water extract produced using Malaysian Agricultural Research and Development Institute (MARDI) Monascus purpureus strains in mice fed with high cholesterol diet. Absence of monacolin-k, lower level of γ-aminobutyric acid (GABA), higher content of total amino acids, and antioxidant activities were detected in MARDI fermented red yeast rice water extract (MFRYR). In vivo MFRYR treatment on hypercholesterolemic mice recorded similar lipid lowering effect as commercial red yeast rice extract (CRYR) as it helps to reduce the elevated serum liver enzyme and increased the antioxidant levels in liver. This effect was also associated with the upregulation of apolipoproteins-E and inhibition of Von Willebrand factor expression. In summary, MFRYR enriched in antioxidant and amino acid without monacolin-k showed similar hypocholesterolemic effect as CRYR that was rich in monacolin-k and GABA.Entities:
Year: 2014 PMID: 25031606 PMCID: PMC4083602 DOI: 10.1155/2014/707829
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Monacolin-k, GABA, total amino acid (free and essential), total phenolic content, and FRAP antioxidant activity of nonfermented rice, MARDI fermented red yeast rice water extract (MFRYR), and commercial red yeast rice extract (CRYR).
| Nonfermented rice | MFRYR | CRYR | |
|---|---|---|---|
| Monacolin-k (µg/g sample) | ND | ND | 182.61 ± 0.02 |
| GABA (g/100 g sample) | ND | 0.14 ± 0.01 | 0.48 ± 0.03 |
| Total free amino acid (g/100 g sample) | ND | 3.33 ± 0.54 | 0.03 ± 0.01 |
| Total essential amino acid (g/100 g sample) | ND | 1.32 ± 0.26 | 0.03 ± 0.01 |
| Total phenolic content (µg GAE/mg sample) | 7.60 ± 0.10 | 16.20 ± 0.10 | 0.81 ± 0.10 |
| FRAP (mg ascorbic acid equivalent (AAE)/g sample) | 29.80 ± 0.01 | 74.04 ± 0.02 | 5.40 ± 0.02 |
ND: not detected; values were mean ± standard deviation of three independent experiments.
Blood serum lipid and liver profile.
| Treatment | Cholesterol (mg/dL) | Triglyceride (mg/dL) | LDL (mg/dL) | HDL (mg/dL) | ALT (U/L) | ALP (U/L) | AST (U/L) |
|---|---|---|---|---|---|---|---|
| Group 1 ( | 115.05 ± 10.53∗ | 177.11 ± 13.19∗ | 39.00 ± 2.39∗ | 47.19 ± 3.17∗ | 62.50 ± 3.55∗ | 90.13 ± 4.45∗ | 120.42 ± 13.05∗ |
| Group 2 ( | 230.47 ± 15.99 | 264.33 ± 23.40 | 113.85 ± 3.90 | 56.55 ± 4.29 | 277.20 ± 9.76 | 127.83 ± 4.29 | 320.13 ± 30.71 |
| Group 3 ( | 201.72 ± 24.57 | 202.03 ± 25.86 | 62.40 ± 1.56∗ | 64.16 ± 1.95∗ | 155.33 ± 9.73∗ | 106.75 ± 4.69∗ | 170.49 ± 31.69∗ |
| Group 4 ( | 179.85 ± 10.12∗ | 171.30 ± 12.60∗ | 44.28 ± 4.33∗ | 70.59 ± 6.17∗ | 173.13 ± 5.58∗ | 105.80 ± 1.08∗ | 181.16 ± 17.59∗ |
| Group 5 ( | 181.07 ± 11.06∗ | 176.22 ± 24.08∗ | 52.26 ± 3.12∗ | 77.42 ± 4.29∗ | 263.58 ± 5.08 | 137.00 ± 3.70 | 424.42 ± 43.07∗ |
Values were mean ± standard deviation of 8 animals in each group and significant difference indicated by ∗(P < 0.05) was determined using ANOVA followed by Duncan's multiple range test.
Figure 1Representative histological micrograph of liver sections from groups 1, 2, 4, and 5 of 14-day treatment stained with H&E (×100, Bar = 50 μm). Only untreated group (group 2) showed lipid droplet in the histological section. CV = central vein, LD = lipid droplet, and PV = portal vein.
Liver homogenate lipid peroxidation and SOD enzyme levels.
| Treatment | MDA (nM MDA/mg sample) | SOD (unit SOD/mg sample) |
|---|---|---|
| Group 1 ( | 0.72 ± 0.15∗ | 0.90 ± 0.12∗ |
| Group 2 ( | 2.21 ± 0.13 | 0.60 ± 0.01 |
| Group 3 ( | 1.11 ± 0.20∗ | 0.72 ± 0.09∗ |
| Group 4 ( | 0.90 ± 0.03∗ | 0.83 ± 0.03∗ |
| Group 5 ( | 1.46 ± 0.21∗ | 0.70 ± 0.19∗ |
Values were mean ± standard deviation of 8 animals in each group and significant difference indicated by ∗(P < 0.05) was determined using ANOVA followed by Duncan's multiple range test.
Relative expression of atherosclerosis related gene in blood of 60 mg/kg body weight of MFRYR (group 4) and CRYR (group 5) treated mice as compared to the untreated mice (group 2).
| Genes | Group 4 (MFRYR 60 mg/kg body weight) | Group 5 (CRYR 60 mg/kg body weight) |
|---|---|---|
| Relative expression (fold change) | ||
| ATP-binding cassette transporter 1 (Abca1) | N.S | 2.00 ± 0.02 |
| Apolipoproteins-E (ApoE) |
|
|
| Chemokine (C-C motif) ligand 2 (CCL2) | N.S | −2.00 ± 0.03 |
| CD44 | N.S | −2.01 ± 0.01 |
| Fibronectin (Fn1) | N.S | −2.03 ± 0.01 |
| Integrin, alpha 2 (ITGA2) | N.S | −2.00 ± 0.03 |
| Lipoprotein lipase (LPL) | N.S | −2.00 ± 0.02 |
| Macrophage scavenger receptor 1 (MSR1) | N.S | −2.01 ± 0.04 |
| Neuropeptide Y (Npy) | N.S | −3.85 ± 0.01 |
| Prostaglandin-endoperoxide synthase 1 (PTGS1) | N.S | −2.00 ± 0.03 |
| Selectin P (SELP) | N.S | −2.00 ± 0.05 |
| Transforming growth factor, beta 2 (TGFB2) | N.S | −2.01 ± 0.02 |
| Tumor necrosis factor (TNF) | N.S | −2.00 ± 0.01 |
| Vascular cell adhesion molecule 1 (Vcam1) | N.S | −2.00 ± 0.01 |
| Von Willebrand factor (Vwf) |
|
|
N.S.: not significant, only fold change greater than ±2 was recorded and presented as significant results.